Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.30 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20525192 | 0.80 | — | — | |
| SCHEMBL21859705 | 0.80 | NOS3 (0.41) | PDPK1PIK3CBEGFR | |
| SCHEMBL20517530 | 0.80 | PDPK1 (0.35) | PDPK1PIK3CB | |
| SCHEMBL29429840 | 0.80 | PDPK1 (0.35) | PDPK1PIK3CB | |
| SCHEMBL20517598 | 0.72 | PDPK1 (0.41) | PDPK1PIK3CBEGFR | |
| SCHEMBL31649759 | 0.72 | PDPK1 (0.44) | PDPK1PIK3CB | |
| SCHEMBL31649933 | 0.72 | PDPK1 (0.44) | PDPK1PIK3CB | |
| SCHEMBL38659726 | 0.71 | OPRM1 (0.32) | — | |
| SCHEMBL21827959 | 0.70 | PDPK1 (0.38) | PDPK1PIK3CBEGFR | |
| SCHEMBL21634861 | 0.70 | PDPK1 (0.38) | PDPK1PIK3CBEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117024411-B | Isoquinoline as HPK1 inhibitor | 豪夫迈·罗氏有限公司 | 2026-05-19 | — | — | CN | disclosed |
| EP-3826722-B1 | ISOQUINOLINE COMPOUNDS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2026-02-18 | — | — | EP | disclosed |
| US-12473301-B2 | Isoquinoline compounds for the treatment of cancer | GENENTECH, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-12378249-B2 | Isoquinoline compounds and uses thereof | GENENTECH, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| EP-3860995-B1 | ISOQUINOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2025-04-16 | — | — | EP | disclosed |
| CN-117024411-A | Isoquinoline as HPK1 inhibitor | 豪夫迈·罗氏有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-110709392-B | Isoquinoline as HPK1 inhibitor | 豪夫迈·罗氏有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-11612606-B2 | 8-aminoisoquinoline compounds and uses thereof | GENENTECH, INC. (US) | 2023-03-28 | — | — | US | disclosed |
| US-11566003-B2 | Isoquinolines as inhibitors of HPK1 | GENENTECH, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| EP-3601259-B1 | ISOQUINOLINES AS INHIBITORS OF HPK1 | HOFFMANN LA ROCHE (CH) | 2022-02-23 | — | — | EP | disclosed |
| EP-3826722-A1 | ISOQUINOLINE COMPOUNDS AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2021-06-02 | — | — | EP | disclosed |
| CN-112601584-A | Isoquinoline compounds and uses thereof | 豪夫迈·罗氏有限公司 | 2021-04-02 | — | — | CN | disclosed |
| WO-2020072695-A1 | 8-AMINOISOQUINOLINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2020-04-09 | — | — | WO | disclosed |
| WO-2020072627-A1 | ISOQUINOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2020-04-09 | — | — | WO | disclosed |
| US-20200108075-A1 | 8-AMINOISOQUINOLINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2020-04-09 | — | — | US | disclosed |
| EP-3601259-A1 | ISOQUINOLINES AS INHIBITORS OF HPK1 | H. Hoffnabb-La Roche Ag (CH) | 2020-02-05 | — | — | EP | disclosed |
| WO-2020023560-A1 | ISOQUINOLINE COMPOUNDS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG | 2020-01-30 | — | — | WO | disclosed |
| CN-110709392-A | Isoquinoline as HPK1 inhibitors | 豪夫迈·罗氏有限公司 | 2020-01-17 | — | — | CN | disclosed |
| US-20180282282-A1 | ISOQUINOLINES AS INHIBITORS OF HPK1 | GENENTECH, INC. (US) | 2018-10-04 | — | — | US | disclosed |
| WO-2018183964-A1 | ISOQUINOLINES AS INHIBITORS OF HPK1 | GENENTECH, INC. (US) | 2018-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12378249-B2 | Isoquinoline compounds and uses thereof | HIPK1, HPGDS, IP6K1 | PDPK1 35/4885PIK3CB 918/4885EGFR 4772/4885 |
| US-12473301-B2 | Isoquinoline compounds for the treatment of cancer | PGK1, PHKG1, NEK1 | PDPK1 26/4885PIK3CB 930/4885EGFR 4129/4885 |
| US-20180282282-A1 | ISOQUINOLINES AS INHIBITORS OF HPK1 | HIPK1, HPGDS, IP6K1 | PDPK1 58/4885PIK3CB 1263/4885EGFR 4780/4885 |
| US-11566003-B2 | Isoquinolines as inhibitors of HPK1 | HIPK1, HIPK2, IP6K1 | PDPK1 42/4885PIK3CB 1106/4885EGFR 4767/4885 |
| US-20200108075-A1 | 8-AMINOISOQUINOLINE COMPOUNDS AND USES THEREOF | PHKG1, MAP4K5, HIPK1 | PDPK1 61/4885PIK3CB 1185/4885EGFR 4679/4885 |
| US-11612606-B2 | 8-aminoisoquinoline compounds and uses thereof | PHKG1, MAP4K5, HIPK1 | PDPK1 61/4885PIK3CB 1185/4885EGFR 4679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.